Diabetes Mellitus (DM) is a chronic metabolic disease with complicated complex pathogenesis. Frequency of newly DM arises worldwide and associated with steadily 
increased morbidity and mortality due to DM-related complications. The incretin-based drugs are posed as remedies modulated effects of natural incretin hormones: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic peptide) and dipeptidyl peptidase enzyme 4 (DPP4). At the beginning of the era of the incretin-based therapy the treatment of T2DM with GLP-1 analogs and DPP-4 inhibitors was introduced. In fact, incretin-based drug exposure was associated with clinically significant  cardiovascular protection. However, it is not known whether all GLP-1 analogs and DPP-4 inhibitors are similar in their capacities to improve cardiovascular outcomes or not that is required a continuous studies in this direction.